Business Description
CASI Pharmaceuticals Inc
ISIN : US14757U1097
Total Employee Number:
214Description
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 | |||||
Equity-to-Asset | -1.45 | |||||
Debt-to-Equity | -0.74 | |||||
Debt-to-EBITDA | -0.61 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -47.48 | |||||
Beneish M-Score | -11.99 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -29.3 | |||||
3-Year EBITDA Growth Rate | 2.7 | |||||
3-Year EPS without NRI Growth Rate | -5.4 | |||||
3-Year FCF Growth Rate | 16.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.27 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.36 | |||||
9-Day RSI | 47.55 | |||||
14-Day RSI | 48.45 | |||||
3-1 Month Momentum % | -5.89 | |||||
6-1 Month Momentum % | -86.01 | |||||
12-1 Month Momentum % | -91.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.27 | |||||
Quick Ratio | 0.24 | |||||
Cash Ratio | 0.11 | |||||
Days Inventory | 116.75 | |||||
Days Sales Outstanding | 123.39 | |||||
Days Payable | 43.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.2 | |||||
Shareholder Yield % | -199.91 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 48.65 | |||||
Operating Margin % | -206.84 | |||||
Net Margin % | -232 | |||||
EBITDA Margin % | -217.42 | |||||
FCF Margin % | -100.34 | |||||
OCF Margin % | -100.2 | |||||
ROA % | -136.66 | |||||
ROIC % | -124.3 | |||||
3-Year ROIIC % | -173.2 | |||||
ROC (Joel Greenblatt) % | -382.71 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.11 | |||||
EV-to-EBIT | -0.54 | |||||
EV-to-EBITDA | -0.54 | |||||
EV-to-Revenue | 1.18 | |||||
EV-to-Forward-Revenue | 3.82 | |||||
EV-to-FCF | -1.18 | |||||
Price-to-GF-Value | 0.12 | |||||
Earnings Yield (Greenblatt) % | -185.19 | |||||
FCF Yield % | -777.81 |
CASI Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CASI Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 139 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 62 days | ||
| First quarter earnings results for 2026 | 2026-07-01 | In 4 days | ||
| General meeting for 2025 | 2026-07-01 | In 4 days | ||
| Annual report for 2025 | 2026-05-15 | 0.14 (-17.65%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.34 (-5.99%) | ||
| Guggenheim Healthcare Innovation Conference | 2025-11-12 09:30 | 1.38 (+2.99%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 10:00 | 2.34 (+5.41%) | ||
| Guidance call for 2025 | 2025-09-03 11:30 | 2.30 (+3.60%) | ||
| Second quarter earnings results for 2025 | 2025-08-29 | 2.44 (+11.42%) |
Show
Entries
Guru Commentaries on OTCPK:CASIF
No articles.
Press Release
Articles on CASI Pharmaceuticals Inc
No articles.